Advanced Biomed Completes Acquisition
Ticker: ADVB · Form: 8-K · Filed: Dec 30, 2025 · CIK: 1941029
| Field | Detail |
|---|---|
| Company | Advanced Biomed INC. (ADVB) |
| Form Type | 8-K |
| Filed Date | Dec 30, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $23,000 b |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, definitive-agreement
TL;DR
Advanced Biomed just bought something. Details in the filing.
AI Summary
Advanced Biomed Inc. announced on December 23, 2025, the completion of an acquisition. The company also entered into a material definitive agreement related to this transaction. Further details regarding financial statements and exhibits are included in the filing.
Why It Matters
This filing indicates a significant corporate action, potentially impacting Advanced Biomed's market position and future growth prospects through the integration of acquired assets or operations.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks related to integration, valuation, and market reception, which could impact the company's financial performance.
Key Players & Entities
- Advanced Biomed Inc. (company) — Filer of the 8-K report
- December 23, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 001-42548 (identifier) — SEC file number
FAQ
What was the nature of the material definitive agreement entered into by Advanced Biomed Inc.?
The filing indicates the entry into a material definitive agreement in connection with the completion of an acquisition or disposition of assets, but specific details of the agreement are not provided in this summary.
What specific assets or companies were acquired by Advanced Biomed Inc.?
The filing states the completion of an acquisition or disposition of assets, but does not specify the names of the acquired entities or assets.
When did the reported acquisition event occur?
The earliest event reported in the filing occurred on December 23, 2025.
What is the principal executive office address for Advanced Biomed Inc.?
The principal executive offices are located at No. 689-85 Xiaodong Road, Yongkang District, Tainan City, Taiwan.
What is the SIC code for Advanced Biomed Inc.?
The Standard Industrial Classification code for Advanced Biomed Inc. is 8071, which corresponds to SERVICES-MEDICAL LABORATORIES.
Filing Stats: 843 words · 3 min read · ~3 pages · Grade level 11.1 · Accepted 2025-12-30 16:00:37
Key Financial Figures
- $23,000 b — ), for an aggregate purchase price of US$23,000 based on a valuation report commissioned
Filing Documents
- ea0271157-8k_advanced.htm (8-K) — 31KB
- ea027115701ex2-1_advanced.htm (EX-2.1) — 92KB
- ea027115701ex99-1_advanced.htm (EX-99.1) — 7KB
- 0001213900-25-126584.txt ( ) — 320KB
- advb-20251223.xsd (EX-101.SCH) — 3KB
- advb-20251223_lab.xml (EX-101.LAB) — 33KB
- advb-20251223_pre.xml (EX-101.PRE) — 22KB
- ea0271157-8k_advanced_htm.xml (XML) — 3KB
01 Entry into a Material Definitive
Item 1.01 Entry into a Material Definitive Agreement. On December 23, 2025, Advanced Biomed Inc. (the " Company ") entered into an agreement (the " Agreement ") with an unrelated third party, Wei Ha Hui (the " Buyer "), pursuant to which the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed (HK) Limited, a Hong Kong company and a wholly owned subsidiary of the Company (the " Hong Kong Subsidiary "), for an aggregate purchase price of US$23,000 based on a valuation report commissioned by the Company, subject to the terms and conditions set forth in the Agreement. All intellectual property owned by the Hong Kong subsidiary, including intellectual property owned by Shanghai Sglcell Biotech Co., Ltd., a wholly owned subsidiary of the Hong Kong subsidiary, was transferred to the Buyer at the closing of this transaction on December 23, 2025. The Agreement and the consummation of the transaction contemplated thereby have been unanimously approved by the Company's board of directors. The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Share Purchase Agreement, which is filed as Exhibit 2.1 to this Current Report on Form 8-K.
01 Completion of Acquisition or Disposition
Item 2.01 Completion of Acquisition or Disposition of Assets. See Item 1.01.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 30, 2025, the Company issued a press release announcing the completion of the disposition of the Hong Kong Subsidiary. A copy of the press release is attached hereto as Exhibit 99.1. The information contained in this Item 7.01 and in Exhibit 99.1 is furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, and such information shall not be deemed to be incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act.
01 Financial Statement and Exhibits
Item 9.01 Financial Statement and Exhibits. Exhibit No. Description 2.1* Agreement between Advanced Biomed Inc. and Wei Ha Hui dated December 23, 2025 99.1 Press release dated December 30, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Portions of this exhibit (indicated by asterisks) have been omitted in accordance with Item 601(b)(10)(iv) of Regulation S-K. If requested by the Commission or its staff, the registrant will promptly provide on a supplemental basis an unredacted copy of the exhibit and its materiality and privacy or confidentiality analyses.
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements, including statements related to the Company's assessment of operational risks. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties are described from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The Company disclaims any obligation to update or revise any forward-looking statements, except as required by law. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Advanced Biomed Inc. Date: December 30, 2025 By: /s/ Yi Lu Yi Lu Chief Executive Officer 2